There are apparently a great many people who at least intermittently use psilocybin. Interestingly, regular dosing with psilocybin has been shown to modestly extend life in mice, but it is likely that only a subset of human users approach the frequency of dosing used in the mouse studies. Finding those humans is ever the challenge, particularly if one wants to study long-term effects on aging. Here, a researcher takes an initial stab at comparing the longevity of psilocybin users with non-users based on publicly available information, but the sample size is so small that it isn't surprising to see a lack of useful results. The study is more interesting as a way to provoke (a) awareness of the evidence for psilocybin to interact with mechanisms of aging, and (b) some thought on what sort of study design would be both practical and useful.
Researchers have reported that psilocybin promotes resilience and extends lifespan in aged mice. This work garnered considerable media attention, with claims that psychedelics might also extend human lifespan. Psychedelics influence longevity-related pathways in rodents such as glucocorticoid receptor signaling and mitochondrial stress tolerance. In light of these findings and in search of some evidence that psychedelics can indeed extend human lifespan, we examined historical mortality patterns of psychedelic personalities (researchers and advocates who had documented, mostly self-claimed, psychedelic use) and compared this group to biomedical researchers (cancer and aging).
Using publicly available records, we identified individuals who died between 2010 and 2025: (i) psychedelic personalities with documented personal use (n = 11), (ii) cancer researchers (n = 12), and (iii) aging researchers (n = 5). Deaths before age 60 were excluded. Conditional life expectancy at age 40 for their birth cohorts (≈73-76 years, US/UK data) was used as a baseline. All three groups lived well beyond population averages, consistent with the survival advantage of highly educated professionals. Crucially, the psychedelic personalities did not outlive their biomedical peers.
Thus, while researchers have provided compelling mechanistic data in mice, translation to humans requires dose-specific and longitudinal studies to identify whether psychedelics such as psilocybin do indeed have some role in extending lifespan.
Link: https://doi.org/10.1038/s41514-026-00380-y
View the full article at FightAging
